Apogee Therapeutics, Inc. (APGE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$135.07-0.01%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APGE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 0.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
APGE — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-09-03
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures in the Introductory Note are incorporated herein by reference. On September 3, 2026, the Company (i) notified the Nasdaq Global Market (“Nasdaq”) of the consummation of the Merger and its intent to remove all Company Common Stock from Nasdaq and (ii) requested that Nasdaq (A) maintain the halt in trading of Company Common Stock, which was effective following the closing of afte…
Why it matters: This acquisition could improve Apogee's skills and market position. It may create new growth.
Supportive ifDetails on how Andor LLC will be added and what it will bring.
Worry ifThere are no updates or signs of issues in the acquisition process.
Why it matters: This agreement could lead to new treatments, impacting future revenue and growth.
Supportive ifWatch for news about progress from the IL-31R Discovery Agreement with Paragon.
Worry ifNo updates or bad news about the IL-31R Discovery Agreement.
Why it matters: Starting these trials is key for Apogee's growth in treating atopic dermatitis. It shows progress in their pipeline.
Supportive ifPhase 3 trials of zumilokibart start as planned in the second half of 2026.
Worry ifTrials do not start by the end of 2026 or face significant delays.
Why it matters: These trials will test the potential of zumilokibart in new uses. This shows growth chances.
Supportive ifPhase 2 trials for asthma begin in 1H 2027 and EoE in 2H 2026.
Worry ifTrials do not start as planned, indicating potential setbacks in the pipeline.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$16 on $10,000 · ±0.2% | How much price usually moves either way. |
| Bad day | $416 loss on $10,000 · 4.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,463 loss on $10,000 · 24.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good results would confirm the drug's effectiveness and support its market potential. This could enhance investor confidence.
Supportive ifPhase 3 trial results show big gains in EASI-75 scores over placebo.
Worry ifPhase 3 trial results show no big gains or worse results than placebo.
Why it matters: The acquisition is important for Apogee's future. It could improve its market position.
Supportive ifThe acquisition by AbbVie completes as expected in Q3 2026.
Worry ifThe acquisition may be delayed or fail. This would hurt Apogee's plans.
Why it matters: Comparing Apogee to peers like Lilly and AbbVie shows if it can catch up. This is vital for market perception.
Watch forApogee does better than peers with stronger RFP and quality.
Also watch forApogee still falls behind peers with strong RFP and quality.
Why it matters: This agreement gives funding to help with development. Finishing this is important for ongoing projects.
Supportive ifThe revenue share agreement is signed and funding has been received.
Worry ifThe agreement faces delays or fails to provide expected funding.
Why it matters: If the sector grows faster, it could help Apogee's performance. This is important for its recovery.
Supportive ifSector revenue growth speeds up to over 10% each year.
Worry ifSector revenue growth remains below 10% year over year.
Why it matters: This data could prove the therapy works well against a big competitor. It may change future plans.
Supportive ifInterim data from the APG279 study against DUPIXENT will come out in 2H 2026.
Worry ifThe data shows no clear advantage over DUPIXENT. This affects confidence in the pipeline.
Why it matters: This acquisition may improve Apogee's skills and market position. It is a key move.
Supportive ifThe merger with Andor LLC is complete. There is good news about integration.
Worry ifDelays or issues in completing the merger with Andor LLC.
Why it matters: The earnings report will show if Apogee can improve its loss-making status. This is key for investor confidence.
Worry ifEarnings report shows a smaller loss than the previous quarter.
Less concerning ifEarnings report shows a larger loss than the previous quarter.
Why it matters: Changes in leadership can change the company's direction. Watching this can show risks or chances.
Watch forGood news or changes in strategy after the officer changes.
Also watch forNegative news or lack of direction after the departure of key officers.
Why it matters: Good results in these trials would help use zumilokibart more widely. This would boost its market potential.
Supportive ifGood results from the Phase 2 trials of zumilokibart in asthma and EoE are shared.
Worry ifBad results from these trials are reported. This raises concerns about how well the drug works.